Balan Dharvind, Kampan Nirmala Chandralega, Plebanski Magdalena, Abd Aziz Nor Haslinda
Department of Obstetrics and Gynaecology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.
School of Health and Biomedical Sciences, RMIT University, Bundoora, VIC, Australia.
Front Oncol. 2024 May 30;14:1388663. doi: 10.3389/fonc.2024.1388663. eCollection 2024.
Ovarian cancer, a highly fatal gynecological cancer, warrants the need for understanding its heterogeneity. The disease's prevalence and impact are underscored with statistics on mortality rates. Ovarian cancer is categorized into distinct morphological groups, each with its characteristics and prognosis. Despite standard treatments, survival rates remain low due to relapses and chemoresistance. Immune system involvement is evident in ovarian cancer's progression, although the tumor employs immune evasion mechanisms. Immunotherapy, particularly immune checkpoint blockade therapy, is promising, but ovarian cancer's heterogeneity limits its efficacy. Single-cell sequencing technology could be explored as a solution to dissect the heterogeneity within tumor-associated immune cell populations and tumor microenvironments. This cutting-edge technology has the potential to enhance diagnosis, prognosis, and personalized immunotherapy in ovarian cancer, reflecting its broader application in cancer research. The present review focuses on recent advancements and the challenges in applying single-cell transcriptomics to ovarian cancer.
卵巢癌是一种极具致命性的妇科癌症，因此有必要了解其异质性。死亡率统计数据凸显了该疾病的发病率和影响。卵巢癌可分为不同的形态学组，每组都有其特点和预后情况。尽管有标准治疗方法，但由于复发和化疗耐药性，生存率仍然很低。免疫系统参与了卵巢癌的进展，尽管肿瘤采用免疫逃逸机制。免疫疗法，特别是免疫检查点阻断疗法，前景广阔，但卵巢癌的异质性限制了其疗效。单细胞测序技术可作为一种解决方案，用于剖析肿瘤相关免疫细胞群体和肿瘤微环境中的异质性。这项前沿技术有潜力改善卵巢癌的诊断、预后和个性化免疫治疗，这反映了其在癌症研究中的更广泛应用。本综述重点关注单细胞转录组学在卵巢癌应用方面的最新进展和挑战。
